Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder

@article{McGough2005DexmethylphenidateEC,
  title={Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder},
  author={James J. McGough and Caroly S. Pataki and Robert L Suddath},
  journal={Expert Review of Neurotherapeutics},
  year={2005},
  volume={5},
  pages={437 - 441}
}
Medications for attention deficit hyperactivity disorder (ADHD) currently represent the ninth largest segment of the CNS market by sales, with US$2.4 billion spent annually on this condition and 40% annual growth. Stimulant medications remain the most effective ADHD therapies and provide robust improvement in ADHD symptoms in both youth and adults. Current prescribing practices favor extended release preparations due to increased convenience, compliance and tolerability with once-daily dosing… 

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day

Most long-acting stimulants exerted beneficial effects on ADHD symptoms for up to 12 hours as measured by the PERMP; the longest duration of efficacy versus placebo was seen with lisdexamfetamine dimesylate (14 hours postdose).

Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents

When the risks are juxtaposed to the clear efficacy in significantly reducing dysfunctional symptoms of ADHD, benefit-risk analyses support the continued use of these pharmacological treatments for patients with ADHD.

Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth.

  • S. FaraoneE. Giefer
  • Medicine, Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2007
Growth of patients with attention-deficit/hyperactivity disorder treated with MTS should be closely monitored, but in this study, deficits in growth in relation to MTS treatment were not a significant clinical concern for most children.

Neuropharmacology of Attention‐Deficit/Hyperactivity Disorder

This chapter provides an overview of various treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD). While methylphenidate in various forms remains the mainstay of pharmacological

Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence

  • M. Schlander
  • Medicine, Political Science
    Child and adolescent psychiatry and mental health
  • 2007
A more than six-fold increase of pharmaceutical spending for children and adolescents is predicted over the decade from 2002 to 2012, from the perspectives of both the NHS in England and the GKV in Germany.

Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults

Current best practices in adult ADHD are examined, with considerable agreement among these guidelines that both empirical evaluation and ongoing updates as new knowledge emerges will be important for their future development.

Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults

Current best practices in adult ADHD are examined, with considerable agreement among these guidelines that both empirical evaluation and ongoing updates as new knowledge emerges will be important for their future development.

Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents

The present study showed the AE of SGA on FBG and TG, but no effect on BP and WC, and found that children are more prone to develop abnormally high FBG.

References

SHOWING 1-10 OF 45 REFERENCES

New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder

Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.

New drugs for the treatment of attention-deficit/hyperactivity disorder

Atatoxetine, a selective noradrenergic re-uptake inhibitor, is the first non-stimulant compound to receive FDA approval for paediatric and adult ADHD.

Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations

The psychostimulant dl‐methylphenidate (MPH) remains the most common drug therapy in child and adolescent psychiatry for the treatment of attention‐deficit‐hyperactivity disorder (ADHD). Evidence of

Stimulant medications : Current knowledge and unmet needs in pediatrics psychopharmacology

Stimulant treatment studies show robust short-term efficacy and a good safety profile, and longerterm studies are few in number but have produced no conclusive evidence that careful therapeutic use of these medications is harmful.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

d-MPH and d,l- MPH appear to provide similar efficacy, and d-MPh may have longer duration of action after twice-daily dosing, but additional studies are needed to determine the statistical and clinical significance of this possibility.

Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications

The results indicate that for a given dose of methylphenidate, individual differences in DAT blockade are not the main source for the intersubject variability in MP‐induced increases in DA, which suggests that for an equivalent level of D AT blockade, MP would induce smaller DA changes in subjects with low than with high DA cell activity.

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.

Oral methylphenidate is very effective in blocking dopamine transporters, and at the weight-adjusted doses used therapeutically (0.3 to 0.6 mg/kg), it is likely to occupy more than 50% of the dopamineTransporter.